| Revenue growth | 38% YoY FY26 growth, 30% YoY for H2FY26. |
|---|---|
| Margins | Margins contracted slightly due to increased R&D and clinical study investments. |
| Order book | Steady pipeline including Saudi Arabia and North Macedonia government tenders. |
| Demand visibility | Strong visibility in Latin American markets and emerging GLP-1 segment. |
| Management confidence | High, focused on aggressive geographic expansion and B2C segment growth. |
Growth
Consolidated revenue grew 38% for FY26 to ₹854cr; B2C share jumped from 4% to 15%.
Outlook
Targeting 30% B2C revenue share in FY27; planned 40 new product launches by Q1FY27.
Risks
EBITDA margins dipped to 6.57% due to R&D and high-cost clinical trials.
Earnings Call filed with NSE, NSE: REMUS. Summary written with AI assistance from the document.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹946.00
- Market cap
- ₹1,115 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 30.1×Sector 50.4×
- Promoter holding
- 70.95%
- FII holding
- 5.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Dividend
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the migration of its equity shares from the NSE Emerge platform to Main Board.
Remus Pharmaceuticals Merger & Restructuring
Remus Pharmaceuticals will incorporate a new subsidiary in the Dominican Republic for pharmaceutical distribution. The company will hold at least 51% of its share capital.
Remus Pharmaceuticals Management Change
Remus Pharmaceuticals Limited has appointed Mr. Ashutosh Naginbhai Valani as a Non-Executive Independent Director, effective September 2, 2026.
Remus Pharmaceuticals SME to Main Board Migration
Remus Pharmaceuticals' board approved the company's migration from the NSE SME Emerge platform to the Main Board. It also announced a new subsidiary in the Dominican Republic.
Remus Pharmaceuticals Earnings Call: Key Takeaways
Remus Pharmaceuticals delivered 38% YoY consolidated revenue growth for FY26. Management is shifting focus toward higher-margin B2C segments and niche formulations in Latin America and Southeast Asia.